An independent report has been released today by Stevenage Bioscience Catalyst (SBC) that demonstrates its key role in delivering economic benefit from life sciences research and innovation in the UK.
15 start-ups with huge potential have successfully completed the Data-driven Advanced Therapeutics Accelerator (DATA) programme at Stevenage Bioscience Catalyst (SBC), one of Europe’s most important science parks for life sciences.
We interview Joe Healey, CEO and Co-Founder of NanoSyrinx, NanoSyrinx is a discovery-stage synthetic biology biotech developing a novel delivery modality for complex biologics.
We interview Tamas Masztis, Senior Director, Cell Therapy Supply Chain for Europe, Kite, a Gilead Company.
We interview Sharon Brownlow, Chief Business Officer at the Cell & Gene Therapy Catapult, which is a centre of excellence in innovation, with the core purpose of building a world-leading cell and gene therapy sector in the UK as a key part of a global industry.
An impressive panel brought together expertise in product innovation and development, regulatory affairs and the patient voice to consider these challenges and how to address them.